Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Luye Pharma Group (LYPHF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Luye Pharma Group $0.50, price $0.27, upside +85.2%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? No
- Add to watchlist
LP
Thin data
Sep 24, 2026
Thin data
Sep 24, 2026
Luye Pharma Group
LYPHF · USCheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.
✓Fair value $0.5000 · Strongly undervalued (+85.2%)
!Quality 40/100
!Mixed Growth (revenue 5y +2.1 %/yr)
!Thin margins · 9.8% net margin (TTM)
✓Low debt · generates free cash flow
!Moderate moat 45/100
!Evidence only low, so the estimate is less certain
Watch Luye Pharma Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $0.2041 – $0.7500 · fair‑value band $0.3700 – $0.6200 · the $0.2700 price screens below the $0.5000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally.
Show more
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by trauma or surgery, and for treatment of venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes mellitus; Seroquel, Seroquel XR, Erzofri; and Rivastigmine Multi-Day Transdermal, Rotigotine transdermal, Fentanyl, and Buprenorphine patches. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Boyoubei, a denosumab injection for the treatment of postmenopausal women with osteoporosis; and Boyouping, a dulaglutide injection for glycemic control in adults. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; develops, manufactures, and commercialises of biologics; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
Stock analysis
Luye Pharma Group (LYPHF) currently trades at $0.2700, while our model-based Fair Value estimate is $0.5000, implying the stock looks roughly 46.0% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of $0.8300 per share, and 24 of the 24 models we run sit above the $0.2700 price.
Bear case: the Earnings-Based group reads lowest at $0.2800, and 0 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.3700 (bear) to $0.6200 (bull), the price of $0.2700 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Luye Pharma Group reported revenue of 6.1B CNY in FY2025 versus 5.2B CNY in FY2021, a compound +4.3%/yr. Reported net income was 603M CNY in FY2025.
Key figures
Market cap $1.1B · P/E ratio 13.5 · P/S ratio 1.32 · EPS (TTM) $0.0200 · Net margin 9.8% · Return on equity 4.1% · Return on assets (EBIT) 3.8% · Operating margin 19.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (medium confidence).
What moves the price
The share trades about 32% below its 52-week high and 32% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 85%, LYPHF screens cheaper than that median.
Fair Value models
Bear $0.3700
Fair Value $0.5000
Bull $0.6200
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0151 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$0.6000
$0.9700
$1.54
79
Growth DCF
$0.5900
$0.9100
$1.37
78
Owner Earnings
$0.4600
$0.7300
$1.16
75
All 24 models by family
DCF Models
FCF DCF
$0.6000
$0.9700
$1.54
79
Owner Earnings
$0.4600
$0.7300
$1.16
75
5Y Revenue Exit
$0.5200
$0.8300
$1.26
72
5Y EBITDA Exit
$0.7300
$1.27
$1.96
74
5Y P/E Exit
$0.4800
$0.7500
$1.05
70
10Y Revenue Exit
$0.5300
$0.8200
$1.27
66
10Y EBITDA Exit
$0.6700
$1.12
$1.81
67
10Y P/E Exit
$0.5200
$0.7700
$1.11
64
Earnings-Based
Graham-Dodd
$0.1500
$0.7400
$1.02
64
Lynch FV
$0.2000
$0.2800
$0.3700
61
PEG = 1.0
$0.2000
$0.2800
$0.3700
57
EPV
$0.3600
$0.4000
$0.4400
74
Multiples
P/E Multiple
$0.3700
$0.5000
$0.6200
63
P/S Multiple
$0.2900
$0.3800
$0.4800
58
P/B Multiple
$0.2900
$0.3800
$0.4800
55
EV/EBIT
$0.6500
$0.8400
$1.04
66
EV/EBITDA
$0.8800
$1.14
$1.41
67
EV/Revenue
$0.4800
$0.6600
$0.8400
54
Asset-Based
NCAV (Graham)
$0.3000
$0.4000
$0.6000
54
Growth DCF
Growth DCF
$0.5900
$0.9100
$1.37
78
Rev-Margin DCF
$0.5200
$0.8300
$1.23
72
Economic Profit
Residual Income
$0.4200
$0.4000
$0.4100
71
ROIC Compounder
$0.3600
$0.4000
$0.4400
72
Growth Earnings
Growth-Adj P/E
$0.3200
$0.4500
$0.5900
67
Notify me when LYPHF reaches fair value
Put LYPHF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
40/100
Of which business quality 41 · Market factors (momentum, volatility) 22
Profitability
25
Margins and returns on capital today
Quality Growth
35
Are margins and returns improving?
Cashflow
68
Earnings quality: real cash, not paper profit
Fin. Strength
40
Balance sheet, leverage, solvency risk
Investment
28
Disciplined investing over empire-building
Low Volatility
36
Calm price path (market factor)
Momentum
5
Price trend over the last 3–12 months (market factor)
52W Momentum
34
Distance to the 52-week high (market factor)
Net Issuance
44
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Start year 2020 (pandemic). Over 10 years: +9.1% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−14.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.5%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−14.5% vs −3.8%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 20%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about −3.0% a year for the price.
Watch LYPHF, get fair value alerts →
Compare Luye Pharma Group with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €134.45 | €108.94 | −19% |
| Takeda Pharmaceutical Company TAK | $18.90 | $11.45 | −39% |
| Teva Pharmaceutical Industries Limited TEVA | $39.31 | $20.88 | −47% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,852 | ₹1,979 | +7% |
| Galderma Group GALD | CHF 163.00 | CHF 110.32 | −32% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥44.86 | ¥49.35 | +10% |
| Haleon plc HLN | $9.26 | $8.49 | −8% |
| Sandoz Group SDZ | CHF 71.16 | CHF 40.32 | −43% |
| Zoetis Inc ZTS | $70.30 | $110.50 | +57% |
| Divi's Laboratories Limited DIVISLAB | ₹9,620 | ₹1,871 | −81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Luye Pharma Group (LYPHF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.5000 versus the last price from Sep 25, 2026 of $0.2700, about +85% upside (undervalued).
What is the fair value of LYPHF?
Our model-based fair value for Luye Pharma Group is $0.5000 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.2700.
What is the quality score of LYPHF?
Luye Pharma Group has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Luye Pharma Group (LYPHF)?
Our model-based price target is the fair value of $0.5000 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $0.3700, optimistic scenario $0.6200. It is a calculation from audited fundamentals, not an analyst target.
What is the Luye Pharma Group stock forecast for 2026?
Our models put fair value at $0.5000, about +85% upside versus the last price from Sep 25, 2026 of $0.2700 (undervalued). Cautious scenario $0.3700, optimistic scenario $0.6200. The calculation is refreshed regularly with new filings.
What is the revenue of Luye Pharma Group (LYPHF)?
Luye Pharma Group reported trailing-twelve-month revenue of about 6.3B CNY (latest available figure, as of Sep 24, 2026).
What growth is priced into Luye Pharma Group (LYPHF)?
For today's price to be fair in a discounted-cash-flow model, Luye Pharma Group would have to grow free cash flow by -1.4 % per year for five years (discount rate 10.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of LYPHF use?
Our models discount Luye Pharma Group at 10.8 %: a base by market capitalisation (small), damped by beta 0.86, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Luye Pharma Group that is -1.4 % per year a year over ten years, using the same discount rate (10.8 %) and the same formula as our fair value.
How much growth has Luye Pharma Group (LYPHF) delivered so far?
Over the past 5 years revenue at Luye Pharma Group grew +2.1 % a year. The price currently implies -1.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Luye Pharma Group (LYPHF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Luye Pharma Group (-1.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Luye Pharma Group (LYPHF)?
The free-cash-flow yield on the price is 11.07 %: that much free cash flow Luye Pharma Group produces per unit of market value. When it exceeds the discount rate of our models (10.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Luye Pharma Group (LYPHF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Luye Pharma Group it is $0.5000 per share (as of Sep 24, 2026), against a price of $0.2700. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Luye Pharma Group stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LYPHF trades below its calculated fair value: price $0.2700, fair value $0.5000, a gap of about +85% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LYPHF?
No. The price is what the market pays today ($0.2700); the fair value is what the company's own numbers justify ($0.5000). For Luye Pharma Group the two are $0.2300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Luye Pharma Group worth?
The market values Luye Pharma Group at about $1.1B (market capitalisation, as of Sep 24, 2026). Per share that is $0.2700; our models calculate a fair value of $0.5000 per share.
What do the bullish and bearish scenarios say about LYPHF?
Our models span a range for Luye Pharma Group: cautious scenario $0.3700, base $0.5000, optimistic $0.6200 per share (as of Sep 24, 2026, price $0.2700). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LYPHF?
Luye Pharma Group trades at a price-to-earnings ratio of 13.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.5000 is built from several models across several years.
How solid is the balance sheet of Luye Pharma Group (LYPHF)?
Balance-sheet figures for Luye Pharma Group (as of Sep 24, 2026): return on equity 4.1%, debt of 0.17 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is LYPHF from its 52-week high?
Luye Pharma Group trades at $0.2700, about 32% below its 52-week high of $0.3950 and 32% above the low of $0.2041 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5000 is for.
Which stocks are comparable to Luye Pharma Group?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Luye Pharma Group stock attractive at the current price?
The data as of Sep 24, 2026: price $0.2700, calculated fair value $0.5000 (+85%), Quality Score 40/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LYPHF calculated?
We run Luye Pharma Group through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.5000, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Luye Pharma Group currently trades 46 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Luye Pharma Group (LYPHF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.2700. Our model-based fair value is $0.5000, about +85% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Luye Pharma Group right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.3700). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Luye Pharma Group (LYPHF) come from?
Earnings per share at Luye Pharma Group grew −5.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.7 %, EBIT margin −6.6 %, tax rate −1.9 %, residual (interest, one-offs) −3.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Luye Pharma Group
How large is the market capitalisation of Luye Pharma Group (LYPHF)?
The market capitalisation of Luye Pharma Group is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Luye Pharma Group (LYPHF)?
The price-to-sales ratio of Luye Pharma Group is 1.32 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Luye Pharma Group (LYPHF)?
Earnings per share at Luye Pharma Group are $0.0200 (price ÷ EPS = P/E 13.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Luye Pharma Group (LYPHF)?
The net margin of Luye Pharma Group is 9.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Luye Pharma Group (LYPHF)?
The return on equity (ROE) of Luye Pharma Group is 4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Luye Pharma Group (LYPHF)?
On an EBIT basis the return on assets of Luye Pharma Group is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Luye Pharma Group (LYPHF)?
The operating margin of Luye Pharma Group is 19.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Luye Pharma Group (LYPHF)?
Revenue at Luye Pharma Group is growing +4.7% versus a year earlier (3y avg +0.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Luye Pharma Group (LYPHF)?
Earnings per share at Luye Pharma Group are growing +240% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Luye Pharma Group (LYPHF) carry?
The net debt of Luye Pharma Group is 4.9B CNY (fiscal year 2025, ≈ 6.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Luye Pharma Group in the live analysis
One click puts Luye Pharma Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.